Hyloris announces submission of Maxigesic® IV packaging
Additional extractable & leachable data generated by an accredited lab facility located in North AmericaResults analyzed and evaluated by toxicological...
Source: globenewswire.com
05b2 News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from 05b2. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In 05b2 Today - Breaking & Trending Today
Hyloris Announces Commercial Partnership for Maxigesic® IV
Exclusive licensing and distribution agreement signed with Salus Pharmaceuticals in Lithuania, Estonia, Latvia, Croatia, Slovenia, Serbia, North Macedonia,...
Source: globenewswire.com
Petros Pharmaceuticals to Pursue 505(B)(2) Pathway for H-100, Company's Novel Topical Investigational Treatment for Peyronie's Disease
Petros Pharmaceuticals, Inc. announces today they will be pursuing the 505(b)(2) pathway for its investigational agent, H-100™, a novel, patented, non-invasive topical treatment being developed for Peyronie’s disease, a condition impacting more than 1 in 10 men in the US.
Source: biospace.com
Petros Pharmaceuticals to Pursue 505(B)(2) Pathway for
Company Is Developing H-100 as Potentially the First FDA-Approved, Nanoparticle-Based Topical Treatment Designed to Provide Improved and Sustained Local...
Source: globenewswire.com